Partner With Us NRI

Biocon Ltd share Price

Company details

6M Return 33.27%
1Y Return -4.08%
Mkt Cap.(Cr) 31,791.89
Volume 980,849
Div Yield 0.57%
OI Chg %
Volume 980,849

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Steady performance; focus on Viatris integration...
About The Stock

     Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene). Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris’ biosimilars assets for US$3.335 billion. Biocon Biologics entered into a strategic alliance with SILS for access to 100 million vaccine doses per annum for 15 years.

    • Biosimilar US pipeline: (approvals - Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab
    • In generics, it is among the world’s largest manufacturers of immunosuppressant and statin APIs
    • Revenue breakup FY22: Biosimilars (41%), Generics (28%), CRAMS (31%)

    Biocon reported strong revenues driven by all three segments.

    • Revenue was up 31% YoY to ₹ 2409 crore
    • EBITDA in Q4FY22 was ₹ 592 crore, up 36% YoY with margins at 24.6%
    • Consequent adjusted PAT was at ₹ 239 crore (down 6% YoY)

Click here for full recommendation

Research view on more stocks

Biotechnology company Biocon announced Q1FY24 results:

  • Consolidated revenues for Q1FY24 grew 59% YoY to Rs 3,516 crore.
  • Core EBITDA grew 42% to Rs 936 crore, representing healthy core operating margins of 28%
  • Net R&D investments for Q1FY24 grew by 59% to Rs 315 crore, representing 12% of revenues ex-Syngene.
  • EBITDA for Q1FY24 increased by 69% to Rs 808 crore, representing an EBITDA margin of 23% versus 22% in Q1FY23.
  • Depreciation, amortisation, and interest increased by Rs 353 crores over last year. This is primarily related to the biosimilar business acquisition cost.
  • Consequently, profit before tax stood at Rs 184 crore.
  • Net profit for Q1FY24, before minority interest was Rs 149 crore.
  • Net profit for Q1FY24 stood at Rs 101 crore. 

"We have had a strong start to the year. At a consolidated level, revenues rose 59% YoY to Rs 3,516 crore driven primarily by the 106% jump in Biosimilars revenue. Research Services revenue rose 25%, and Generics reported 15% growth. Our Core EBITDA for the quarter was up 42% at Rs 936 crore, reflecting a margin of 28%. R&D investments at Rs 315 crore increased by Rs 117 crore this quarter, reflecting our advancing pipeline, which will support future growth.

Our key biosimilars are gaining traction in both U.S. and Europe with Fulphila becoming the leading biosimilar Pegfilgrastim in the U.S. and biosimilar Glargine’s market share crossing the 12% mark. A higher new prescription share reflects the prescriber confidence in our portfolio and the overall improvement in the adoption of biosimilars.” said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics.

“The Generics business delivered a healthy 15% YoY revenue growth, driven by growth in our formulations business in the U.S. and new product launches in a few key MoW markets. We also saw a volume increase in immunosuppressant APIs.

Our product pipeline continues to advance with an approval for Vigabatrin tablets and a tentative approval for Lenalidomide capsules in the U.S., and for Mycophenolic acid tablets in Europe. The positive outcome of the two U.S. FDA inspections at our Hyderabad API and Bengaluru OSD sites will help in accelerating new product approvals.

We continue to make investments for future growth, with work having commenced on the expansion of our peptide and fermentation capacities in Bengaluru, with a timeline for completion in the second half of FY25.” said Siddharth Mittal, CEO & Managing Director, Biocon.


Result PDF

View Other Company Results


Investment recommendation
Steady performance; focus on Viatris integration...
Call Date
16 Feb 2023
Entry Price 241.00
Target Price 230.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Biocon Ltd Stocks COMPARISION


Equity Capital: 17,866.90 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 19,065.79 -9,437.36
LAST 3M 48,885.55 -453.72
LAST 6M 53,246.77 148,781.31
LAST 12M 137,184.48 160,910.46

Biocon Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
Registered Address

20th KM Hosur Road Hebbagodi, Electronic City P O, Bangalore, Karnataka, 560100

Tel : 91-80-28082808
Email : co.secretary:biocon.com
Website : http://www.biocon.com

Karvy Computershare Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 532523
Book Closure Date (Month) :
BSE Group : A
ISIN : INE376G01013

FAQ’s on Biocon Ltd Shares

You can buy Biocon Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Biocon Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Sep 27, 2023 12:34 PM the closing price of Biocon Ltd was ₹ 264.80.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 27, 2023 12:34 PM, the market cap of Biocon Ltd stood at ₹ 31,791.89.

The latest PE ratio of Biocon Ltd as of Sep 27, 2023 12:34 PM is 44.86

The latest PB ratio of Biocon Ltd as of Sep 27, 2023 12:34 PM is 0.57

The 52-week high of Biocon Ltd is ₹ 299.15 while the 52-week low is ₹ 191.55

According to analyst recommendations, Biocon Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app